Cantor Fitzgerald Raises Kadmon (NYSE:KDMN) Price Target to $10.00

Kadmon (NYSE:KDMN) had its target price boosted by Cantor Fitzgerald from $8.00 to $10.00 in a research note issued on Tuesday, The Fly reports. The firm currently has an “overweight” rating on the stock. Cantor Fitzgerald’s price objective points to a potential upside of 171.00% from the company’s current price.

Several other research firms have also recently weighed in on KDMN. ValuEngine raised shares of Kadmon from a “sell” rating to a “hold” rating in a research note on Wednesday, October 30th. Zacks Investment Research lowered shares of Kadmon from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. Kadmon presently has a consensus rating of “Buy” and a consensus price target of $9.35.

KDMN opened at $3.69 on Tuesday. The stock has a market capitalization of $390.37 million, a price-to-earnings ratio of -3.58 and a beta of 2.22. The company has a fifty day moving average of $2.80 and a 200 day moving average of $2.42. Kadmon has a fifty-two week low of $1.63 and a fifty-two week high of $3.74. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.29 and a current ratio of 2.29.

A number of hedge funds have recently added to or reduced their stakes in KDMN. Boxer Capital LLC bought a new position in Kadmon during the second quarter valued at $7,597,000. BlackRock Inc. lifted its holdings in Kadmon by 23.5% during the 2nd quarter. BlackRock Inc. now owns 8,428,750 shares of the company’s stock valued at $17,363,000 after buying an additional 1,605,568 shares in the last quarter. Sofinnova Investments Inc. lifted its holdings in Kadmon by 31.8% during the 2nd quarter. Sofinnova Investments Inc. now owns 2,204,202 shares of the company’s stock valued at $4,540,000 after buying an additional 532,432 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Kadmon by 5.9% during the 2nd quarter. Vanguard Group Inc. now owns 5,713,561 shares of the company’s stock valued at $11,770,000 after buying an additional 320,710 shares in the last quarter. Finally, AE Wealth Management LLC lifted its holdings in Kadmon by 52.9% during the 2nd quarter. AE Wealth Management LLC now owns 532,855 shares of the company’s stock valued at $1,098,000 after buying an additional 184,364 shares in the last quarter. Institutional investors and hedge funds own 76.63% of the company’s stock.

About Kadmon

Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.

Recommended Story: What is the Dividend Aristocrat Index?

The Fly

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.